Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Tumor samples (archival FFPE and optional de novo biopsy) and blood samples: Molecular screening
Study summary
The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.
Eligibility
Primary outcome measure(s)
- Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial. — At the end of study (5 years)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Léon Bérard | Lyon | France | Recruiting |
More Centre Leon Berard trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05380414 on ClinicalTrials.gov ↗ ← All trials in France